KDR and hereditary clear cell renal cell carcinoma: Although potent VEGFR2 inhibitors are currently available (such as the pan VEGFR inhibitor Axitinib, approved to treat renal cell carcinoma [44]), it is highly possible that using single target inhibitors secondary resistance will occur.